Home › Essential Thrombocythemia › Washington
Essential Thrombocythemia clinical trials in Washington
3 studies for Essential Thrombocythemia are looking for participants at sites in Washington.
Cities in Washington
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
- University of Washington - Fred Hutch Cancer Center, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07623200A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
- Site US22, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT07849231Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04282187From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.